SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022
Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis.BMC health services research · 2024Pooled it
- The prevalence of multiple sclerosis (MS) in Oceania, a systematic review, and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis.PloS one · 2022Pooled it
- Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.Scientific reports · 2024Trial
- The Role of Self-Compassion on Self-Care With the Mediating Role of Illness Perception in Patients With Multiple Sclerosis Referred to Sina Hospital: Based on the Leventhal Model.Brain and behavior · 2026Article
- Reproductive, Dietary, and Physical Activity Factors Associated With Multiple Sclerosis: A Case-Control Study.Health science reports · 2026Article
- Deep learning-based neuroanatomical profiling reveals population-specific brain changes in multiple sclerosis: a large-scale Middle Eastern study.BMC medical imaging · 2026Observational
- Investigating Depression and MRI Associations in Middle Eastern Relapsing-Remitting Multiple Sclerosis.Journal of biomedical physics & engineering · 2026Article
- Effect of Foot Reflexology on Restless Legs Syndrome and Sleep Quality in Female Patients With Multiple Sclerosis: A Randomized, Double-Blind Clinical Trial.Neurology research international · 2026Article
- Invisible symptoms and associated factors in multiple sclerosis patients.Journal of education and health promotion · 2026Article
- Effect of action observation training on hand function, upper extremity strength and fatigue in individuals with multiple sclerosis.IBRO neuroscience reports · 2025Article
- Sleep disorders and associated factors in multiple sclerosis patients: a cross-sectional study in Iran.BMC neurology · 2025Article
- Investigating the Psychometric Properties of the Persian Version of the Revised Illness Perception Questionnaire in a Sample of Patients With Multiple Sclerosis.Brain and behavior · 2025Article
- The effects of Leventhal's self-regulation model-based educational intervention on stress, anxiety, and depression in women with multiple sclerosis: a randomized educational trial.Frontiers in neurology · 2025Article
- Long-term effects of air pollution on the incidence and progression of multiple sclerosis: A population cohort study in Isfahan, Iran.PloS one · 2025Article
- Examination of High-Level Language Skills in 2 Phases of Multiple Sclerosis (Relapsing-Remitting & Secondary Progressive) in Comparison With Healthy Counterparts.Medical journal of the Islamic Republic of Iran · 2025Article
- Living With Multiple Sclerosis: The Rainbow of Inspiring Experiences and Resilience in the Face of the Disease.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Social stigma and its relationship with quality of life in multiple sclerosis patients.BMC neurology · 2023Article
- Cross-reactivity betweenHeliyon · 2023Article
- Social support and anxiety correlation with resilience in patients with multiple sclerosis during COVID-19 pandemic.Current journal of neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevalence of multiple sclerosis (MS) is increasing world-wide. Iran is not exception. As the prevalence reported differently in various provinces, we designed this systematic review and meta-analysis to estimate pooled prevalence of MS in Iran.
methodsTwo researchers systematically searched Scientific Information Database (SID), PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched references of the included studies, and conference abstracts which were published up to April 2021. The search strategy included the MeSH and text words as ((((Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Dis-seminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating)) AND (prevalence OR prevalences OR period prevalence OR prevalence, period OR point prevalence OR point prevalences OR prevalence, point) AND (Iran OR Islamic Republic of Iran)))).
resultsThe literature search revealed 2817 articles, after deleting duplicates 2184 remained. For the systematic review, 34 studies were included. The prevalence is highest in Tehran and lowest in Khuzestan and Sistan-Baluchestan provinces. The pooled prevalence was 0.001 (95% CI: 0.000-0.001) (I
conclusionThe results of this study show that the pooled prevalence of MS in Iran is 100 in 100,000 which is high. The prevalence in provinces increases dramatically.
Indexed as
Identifiers
34787755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.